Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives $10.80 Consensus Price Target from Analysts

Vigil Neuroscience, Inc. (NASDAQ:VIGL) has been given a consensus recommendation of “Hold” by the ten ratings firms that are covering the stock, Marketbeat Ratings reports. Ten analysts have rated the stock with a hold rating. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $10.80.

Several equities analysts have issued reports on the company. JMP Securities reissued a “market perform” rating on shares of Vigil Neuroscience in a research note on Thursday, May 22nd. Stifel Nicolaus lowered shares of Vigil Neuroscience from a “buy” rating to a “hold” rating and lowered their price objective for the company from $11.00 to $8.00 in a research note on Wednesday, May 28th. Wedbush lowered shares of Vigil Neuroscience from a “strong-buy” rating to a “hold” rating and cut their target price for the stock from $13.00 to $8.00 in a research note on Thursday, May 22nd. Mizuho cut shares of Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Friday, May 23rd. Finally, HC Wainwright downgraded shares of Vigil Neuroscience from a “buy” rating to a “neutral” rating and decreased their price target for the company from $14.00 to $8.00 in a research note on Tuesday, May 27th.

Vigil Neuroscience Trading Up 0.5%

Shares of Vigil Neuroscience stock opened at $7.92 on Tuesday. The business has a 50-day moving average price of $4.54 and a two-hundred day moving average price of $2.94. Vigil Neuroscience has a 1-year low of $1.31 and a 1-year high of $7.95. The company has a market cap of $369.63 million, a P/E ratio of -3.86 and a beta of 3.43.

Vigil Neuroscience (NASDAQ:VIGL) last announced its earnings results on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.04. Equities research analysts forecast that Vigil Neuroscience will post -2.07 EPS for the current fiscal year.

Institutional Trading of Vigil Neuroscience

Hedge funds have recently bought and sold shares of the business. Blair William & Co. IL bought a new position in shares of Vigil Neuroscience in the fourth quarter valued at $551,000. Renaissance Technologies LLC increased its position in shares of Vigil Neuroscience by 698.5% during the fourth quarter. Renaissance Technologies LLC now owns 367,300 shares of the company’s stock worth $624,000 after acquiring an additional 321,300 shares in the last quarter. Barclays PLC raised its holdings in shares of Vigil Neuroscience by 43.6% in the 4th quarter. Barclays PLC now owns 64,049 shares of the company’s stock worth $109,000 after acquiring an additional 19,436 shares during the last quarter. Marshall Wace LLP lifted its position in Vigil Neuroscience by 85.3% in the 4th quarter. Marshall Wace LLP now owns 266,895 shares of the company’s stock valued at $454,000 after acquiring an additional 122,853 shares in the last quarter. Finally, Boothbay Fund Management LLC bought a new position in Vigil Neuroscience in the 4th quarter valued at about $249,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.